Aktis Oncology, Inc. Common stock (NASDAQ: AKTS) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AKTIS ONCOLOGY, INC. COMMON STOCK

Aktis Oncology, Inc. Common stock (NASDAQ: AKTS)
Listen to this Section


$19.15
-0.7400 ( -3.72% ) 56.6K

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Market Data


Open $19.15
Previous Close $19.89
Volume 56.6K
Market Cap $1.10B
Day Range $19.06 - $20.98
52 Week Range $14.72 - $29.16
Shares Outstanding 55.28M
Change % -3.72%
Net Change ▼ -0.7400
Insider Ownership N/A
Exchange NASDAQ
Sector
IndustryPHARMACEUTICAL PREPARATIONS
IPO Year2026
CountryUnited States
UnderwriterJ.P. Morgan, BofA Securities, Leerink Partners, TD Cowen, more

Insider Ownership Transactions

Total Amount Purchased: 559,467.00

Date Type Amount Purchased Purchaser
2023-11-08 Sale -108250.00 RUDY SUZANNE B
2023-11-08 Sale -78250.00 McMahon Jeffrey
2023-11-08 Sale -83500.00 McGuire James Michael
2023-11-08 Sale -38250.00 Denbaars Steven
2023-11-08 Sale -185000.00 Petock Michelle
2023-09-28 Sale -80000.00 Shealy Jeffrey B.
2023-09-15 Sale -40000.00 Boller Kenneth
2023-09-15 Sale -40000.00 Aichele David
2023-09-13 Sale -3900.00 Boller Kenneth
2023-09-13 Sale -5300.00 Aichele David

SEC Filings


No data available for selected period.

Latest News


× Before browsing our site, please accept our cookies policy